Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lovastatin preserves renal function in experimental diabetes.

S R Inman1, N T Stowe, M D Cressman

  • 1Department of Urology, Loyola University Stritch School of Medicine, Maywood, Illinois, USA.

The American Journal of the Medical Sciences
|April 21, 1999
PubMed
Summary

This study shows that lovastatin and enalapril protect kidney function in diabetic rats by preserving glomerular filtration rate and reducing injury. These benefits appear independent of cholesterol-lowering effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of alternative behavioral observation methods in young broiler chickens.

Poultry science·2019
Same author

Referral patterns of primary care physicians for chronic kidney disease in general population and geriatric patients.

Clinical nephrology·2010
Same author

Pathogenesis and treatment of resistant hypertension.

Minerva medica·2003
Same author

Local carboplatin delivery and tissue distribution in livers after radiofrequency ablation.

Journal of biomedical materials research. Part A·2003
Same author

Ischaemic nephropathy: can we preserve renal function?

Journal of human hypertension·2002
Same author

New strategies for blood pressure control.

Journal of human hypertension·2002

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic nephropathy is a major complication of diabetes mellitus.
  • Hyperlipidemia is linked to glomerulosclerosis, but lipid-lowering agents' role in diabetic nephropathy is understudied.
  • Understanding renoprotective mechanisms in diabetic kidney disease is crucial.

Purpose of the Study:

  • To investigate the renoprotective effects of lovastatin and enalapril in a rat model of diabetic nephropathy.
  • To test the hypothesis that these agents can preserve renal function and reduce glomerular injury.
  • To explore whether lovastatin's effects are independent of its lipid-lowering properties.

Main Methods:

  • Streptozotocin-induced diabetic Wistar rats were divided into five groups: non-diabetic, diabetic (insulin only), lovastatin, enalapril, and lovastatin plus enalapril.

Related Experiment Videos

  • Animals were treated for 8 weeks.
  • Glomerular filtration rate (GFR) was measured via insulin clearance, and kidney histology was assessed for mesangial matrix injury.

    • Main Results:

    • Diabetic rats showed significantly reduced GFR and elevated blood glucose and lipids.
    • Lovastatin and enalapril treatments individually preserved GFR compared to diabetic controls (P < 0.05).
    • The combination therapy showed a higher GFR than enalapril alone (P < 0.05) and reduced mesangial matrix injury, with no significant change in plasma lipid levels.

    Conclusions:

    • Lovastatin and enalapril effectively abrogate the decline in GFR and reduce glomerular injury in diabetic rats.
    • Lovastatin demonstrates a direct renal protective effect independent of its lipid-lowering action.
    • Both agents, individually and in combination, offer significant renoprotection in this diabetic nephropathy model.